FITC anti-human CD3 Antibody

Pricing & Availability
HIT3a (See other available formats)
Regulatory Status
V CD03.05
Other Names
T3, CD3ε
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
Human peripheral blood lymphocytes stained with HIT3a FITC
  • HIT3a_FITC_073004
    Human peripheral blood lymphocytes stained with HIT3a FITC
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
300305 25 tests 18€
Check Availability

Need larger quantities of this item?
Request Bulk Quote
300306 100 tests 44€
Check Availability

Need larger quantities of this item?
Request Bulk Quote

CD3ε is a 20 kD chain of the CD3/T-cell receptor (TCR) complex which is composed of two CD3ε, one CD3γ, one CD3δ, one CD3ζ (CD247), and a T-cell receptor (α/β or γ/δ) heterodimer. It is found on all mature T lymphocytes, NK-T cells, and some thymocytes. CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal transduction, and T cell activation.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Antibody Type
Host Species
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported (for the relevant formats) applications include: immunohistochemical staining of acetone-fixed frozen sections, immunoprecipitation, and activation of T lymphocytes4-7. The HIT3a antibody is able to stimulate T cell activation. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 300314). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 300332) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
  3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
  4. Sedelies KA, et al. 2004. J. Biol. Chem. 279:26581. (Activ)
  5. Rivollier A, et al. 2004. Blood 104:4029. (Activ)
  6. Scharschmidt E, et al. 2004. Mol. Cell Biol. 24:3860. (Activ)
  7. Smeltz RB. 2007. J. Immunol. 178:4786. (Activ)
Product Citations
  1. Budde H, et al. 2017. Ann Hematol. 10.1007/s00277-017-2999-5. PubMed
  2. Zhou Y, et al. 2020. Cancer Cell. 38(6):818-828.e5. PubMed
  3. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  4. Wang P, et al. 2023. Front Immunol. 13:1104329. PubMed
  5. Cui B, et al. 2023. Int Immunopharmacol. 114:109541. PubMed
  6. Sun L, et al. 2023. Mol Med Rep. 27: . PubMed
  7. Xu QH, et al. 2023. Am J Reprod Immunol. 89:e13581. PubMed
  8. Chen L, et al. 2023. Immunology. 169:204. PubMed
  9. Vyasamneni R, et al. 2023. Cell Rep Methods. 3:100388. PubMed
  10. Nisa BU, et al. 2023. Life (Basel). 13:. PubMed
  11. Tang C, et al. 2023. Nat Commun. 14:1493. PubMed
  12. Wu X, et al. 2023. iScience. 26:106559. PubMed
  13. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  14. Rosa TLSA, et al. 2022. Front Med (Lausanne). 9:899998. PubMed
  15. Ding L, et al. 2021. Cancers (Basel). 13:. PubMed
  16. Delvecchio FR, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1543. PubMed
  17. Parameswaran R, et al. 2016. Nat Commun. 7: 11154. PubMed
  18. Poran A, et al. 2020. Cell Reports Medicine. 1(8):100141. PubMed
  19. Wang H, et al. 2022. Front Immunol. 13:852436. PubMed
  20. Wang M, et al. 2022. Immun Inflamm Dis. 10:e626. PubMed
  21. Imbrechts M, et al. 2022. iScience. 25:104705. PubMed
  22. Jiang Q, et al. 2021. Cell Reports. 34(4):108670. PubMed
  23. Mondala PK, et al. 2021. Cell Stem Cell. 28(4):623-636.e9. PubMed
  24. Bu S, et al. 2019. Int J Oncol. 55:179. PubMed
  25. Sutton HJ, et al. 2021. Cell Reports. 34(6):108684. PubMed
  26. Turner JS, et al. 2021. Nature. 596:109. PubMed
  27. Dean JW, et al. 2020. J Autoimmun. 108:102417. PubMed
  28. Hu W, et al. 2021. Vaccines (Basel). 9:. PubMed
  29. Sanchez-Vargas LA, et al. 2020. Viruses. 12:. PubMed
  30. Huang B, et al. 2020. Cell. 179(5):1160-1176.e24.. PubMed
  31. Stuart T, et al. 2019. Cell. 177:1888. PubMed
  32. Washburn ML, et al. 2019. J Immunol. 203:1897. PubMed
  33. Gingrich AA, et al. 2021. Front Immunol. 12:670309. PubMed
  34. Wu H, et al. 2022. Biomolecules. 12:. PubMed
  35. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  36. Ott PA, et al. 2020. Cell. 183(2):347-362.e24. PubMed
  37. Pellegrini JM, et al. 2021. Sci Rep. 11:13559. PubMed
  38. Du Y, et al. 2022. Nat Commun. 13:231. PubMed
  39. Wang X, et al. 2021. Adv Sci (Weinh). 8:e2101447. PubMed
  40. Zhang J, et al. 2022. Nature. 609:369. PubMed
  41. Urlaub D, et al. 2019. Arthritis Res Ther. 1.067361111. PubMed
  42. Idorn M, et al. 2018. Oncoimmunology. 7:e1412029. PubMed
  43. Omer OS, et al. 2020. Methods Mol Biol. 2121:199. PubMed
  44. Guo S, et al. 2021. Stem Cells Int. 2021:9989790. PubMed
  45. Abolhassani H, et al. 2017. J Exp Med . 214(1):91-106. PubMed
  46. Janela B, et al. 2019. Immunity. 50:1069. PubMed
  47. Bourges C, et al. 2020. EMBO Mol Med. 12:e12112. PubMed
  48. Grant R, et al. 2021. Methods Protoc. 4:. PubMed
  49. Murdock BJ, et al. 2021. JCI Insight. 6:. PubMed
  50. Liu Y, et al. 2020. Oncol Lett. 2369:20. PubMed
  51. Linedale R, et al. 2017. PLoS One. 12:e0175755. PubMed
  52. Motwani MP, et al. 2018. JCI Insight. 3:e94463. PubMed
  53. Elias S, et al. 2020. Haematologica. . PubMed
  54. Jiang Q et al. 2019. Cancer cell. 35(1):81-94 . PubMed
  55. Liu B, et al. 2019. Mol Med Rep. 20:2823. PubMed
  56. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  57. Wu G, et al. 2021. Nat Cancer. 2:1170. PubMed
  58. Walle T, et al. 2022. Sci Adv. 8:eabh4050. PubMed
  59. Wadley AJ, et al. 2020. Brain Behav Immun Health. 3:100049. PubMed
  60. Karlsson J, et al. 2020. Nat Commun. 1.773611111. PubMed
  61. Foote JR, et al. 2019. Front Immunol. 10:188. PubMed
  62. Warthan MD, et al. 2018. Biol Reprod. 98:309. PubMed
  63. Gladkikh A, et al. 2017. Cancer Med. . 10.1002/cam4.1257. PubMed
  64. McGowan J, et al. 2019. Front Immunol. 10:1553. PubMed
  65. Dinh HQ, et al. 2020. Immunity. 53(2):319-334.e6. PubMed
  66. Yang JY, et al. 2020. J Cell Mol Med. . PubMed
  67. Forsberg EMV, et al. 2019. Cancer Res. 79:899. PubMed
AB_314041 (BioLegend Cat. No. 300305)
AB_314042 (BioLegend Cat. No. 300306)

Antigen Details

Ig superfamily, with the subunits of CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) forms CD3/TCR complex, 20 kD

Mature T and NK-T cells, thymocyte differentiation

Antigen recognition, signal transduction, T cell activation
Peptide antigen bound to MHC
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
3. Lanier L, et al. 1986. J. Immunol. 137:2501-2507.

Gene ID
916 View all products for this Gene ID
View information about CD3 on

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.


This product is supplied subject to the terms and conditions, including the limited license, located at ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.


BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.


8999 BioLegend Way, San Diego, CA 92121
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.


Login / Register
Remember me
Forgot your password? Reset password?
Create an Account